Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004358 citationsJournal Articlebronze Open Access

Authors

Rafael Rosell · Institut Català d'Oncologia

Kathleen D. Danenberg

V. Alberola · Hospital Arnau de Vilanova

Gerold Bepler · Moffitt Cancer Center

José Javier Sánchez · Universidad Autónoma de Madrid

Carlos Camps · Hospital General Universitario De Valencia

Mariano Provencio · Hospital Universitario Puerta de Hierro Majadahonda

Abstract

RRM1 mRNA expression is a crucial predictive marker of survival in gemcitabine/cisplatin-treated patients. Genetic testing of RRM1 mRNA expression levels can and should be used to personalize chemotherapy.

Topics & Keywords

Lung Cancer Treatments and Mutations Cholangiocarcinoma and Gallbladder Cancer Studies DNA Repair Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 10, Issue 4, pp. 1318-1325

DOI: 10.1158/1078-0432.ccr-03-0156

Field-Weighted Citation Impact: 24.07